health

February 24, 2026

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or coinsurance benefit designs.

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

TL;DR

  • Novo Nordisk will reduce the U.S. list prices of Wegovy, Ozempic, and Rybelsus by up to 50%, to $675 per month, starting January 1, 2027.
  • The price cuts are intended to lower out-of-pocket costs for insured patients, particularly those with high-deductible health plans or coinsurance.
  • This strategy aims to increase patient access and uptake in the commercial insurance market and improve Novo Nordisk's competitive position against Eli Lilly.
  • The move coincides with new, lower Medicare prices for these drugs, which will be $274 per month starting in 2027, following negotiations under the Inflation Reduction Act.

Continue reading the original article

Made withNostr